Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study

Abstract

BackgroundMicroencapsulated sodium butyrate (MSB) has been previously associated with anti-inflammatory and regenerative properties regarding large bowel mucosa. We aimed to examine a role of MSB in patients with diverticulosis, hypothesizing its potential for reduction of diverticulitis episodes and diverticulitis prevention.MethodsSeventy-three patients with diverticulosis (diagnosed in colonoscopy or/and barium enema or/and CT colography) were recruited for the study and randomized. The investigated group was administered MSB 300 mg daily; the control group was administered placebo. After 12 months, a total of 52 patients completed the study and were subject to analysis (30 subjects and 22 controls). During the study, the number of episodes of diverticulitis (symptomatic diagnosis with acute pain, fever, and leukocytosis), hospitalizations, and surgery performed for diverticulitis were recorded. Additionally, a question regarding subjective improvement of symptoms reflected changes in quality of life during the analysis.ResultsAfter 12 months, the study group noted a significantly decreased number of diverticulitis episodes in comparison to the control group. The subjective quality of life in the study group was higher than in the control group. There were no side effects of the MSB during the therapy.ConclusionsMSB reduces the frequency of diverticulitis episodes, is safe, and improves the quality of life. It can play a role in the prevention of diverticulitis.

The Role of Butyrate, A Histone Deacetylase Inhibitor in Diabetes Mellitus: Experimental Evidence for Therapeutic Intervention

“…Physicochemical characteristics of FBA are more suitable than butyrate for dosing and clinical development [89]. Further, microencapsulated sodium butyrate, a hydroxy propyl future science group The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus Review methyl cellulose and shellac coating of butyrate has been developed for extended and selective delivery of butyrate in colon [90,91]. Although, butyrate-based products are available in the market, but their use is very limited in chronic diseases due to lack of orally administrable formulations as well as poor palatability [32].…”

Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders

“…Slow‐release preparation of oral butyrate, utilising pH‐dependent release mechanisms, is an alternative approach to colonic enema that had benefits in patients with diverticulosis and Crohn's disease in pilot studies . However, this approach has not been further developed and requires testing in larger placebo‐controlled RCTs.…”

Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC

“…NaB has also been used in clinical trials. NaB improved the efficacy of oral mesalazine in active ulcerative colitis (Vernia et al 2000); reduced inflammation in stool of the patients with shigellosis, along with an improvement in rectal histopathology (Raqib et al 2012); reduced the frequency of abdominal pain in patients with irritable bowel syndrome (Banasiewicz et al 2013) and reduced the frequency of diverticulitis episodes (Krokowicz et al 2014). Thus, there is a potential use of NaB, the NRF2 activator, in the prevention of DN.…”